Build Better, Faster, Smarter AI.

BioSymetrics empowers healthcare and biomedical R&D innovation.

 

We created the first biomedical specific machine learning framework and programming language to increase precision, shorten timelines, and improve discovery.

The Augusta™ software platform significantly improves time-to-market and drives innovation.  Augusta 2.0 enables data scientists to automate the tasks of pre-processing and management of disparate data, with integrated analysis, feature engineering, and predictive modeling in a single, easy-to-use framework.

Drug

Discovery

& Research

Biopharma, Pharmaceutical, and CRO’s can rapidly leverage the power of AI and ML to enable lead compound discovery and trials.  Easy to deploy, the Augusta™ framework enables faster pre-processing and model interrogation.

Diagnostics &

Precision

Medicine

Utilize advanced artificial intelligence to classify subpopulations and tailor medical treatment to individual characteristics.  The Augusta™ platform analyzes and draws inferences from vast amounts of data points, improving quality of patient care, enabling cost-effectiveness, reducing readmissions and mortality rates.

Value

Based

Care

Hospitals, healthcare systems, and medical groups can improve institutional operations, finance and research programs.  Applying machine learning (ML) to EMR’s, billing, admissions, radiology, cardiology, neurology, oncology and obstetrics (to name a few).

Products

The AugustaTM platform allows rapid and effective integrated analytics and Machine Learning (ML) on many different kinds of biomedical and healthcare data types. Our AI ML platform capabilities include over 140 data modules that can be leveraged in data science and predictive analytics initiatives.

AugustaTM use cases

Services

We offer turnkey services to our clients and corporate partners, with the aim of assisting organizations and teams in getting the greatest benefit from their data science initiatives. Our track record in massive data analytics including machine learning has been recognized with industry awards and conference speaking opportunities, and ties to our insight and knowledge base about the complexities in biomedical AI.

BioSymetrics services are available in several different ways, from our comprehensive technology solution implementations formalized in licensing agreements, to CRO consulting engagements and ad hoc projects.

MEDIA ADVISORY: BioSymetrics to Demonstrate Usage of Artificial Intelligence for Healthcare and Biomedical R&D Innovation at Collision 2019

By | Event | No Comments

TORONTO – (May 21, 2019) – Biomedical artificial intelligence (AI) company BioSymetrics will be attending Collision 2019, which is being held May 20-23 at the Entercare Centre in Toronto. BioSymetrics is pioneering proprietary data science and machine learning software in order to best optimize medical discovery and life sciences productivity.

The company’s Chief Scientific Officer, Gabe Musso, will be available for meetings at Collision during the HealthConf track on Thursday, May 23, at BioSymetrics’ booth (Booth #B101) and can discuss how BioSymetrics’ inaugural product, the Augusta™ software platform, provides a holistic solution to some of the current industry challenges, including the utilization of good data without bias to feed machine learning models, as well as solving the ability to interrogate multiple models. BioSymetrics simplifies biomedical data science projects by reducing the time spent on data pre-processing, thus ultimately helping to build more effective predictive models that enable solutions to reach the market more quickly.

NOTE: Booth #B101 will be located in a different area on Thursday; please ask for directions at the information desk.

Media & Analyst Briefings

To schedule a briefing with BioSymetrics at Collision, please contact BioSymetrics’ PR team at 774-551-6679 or kgrill@elevatecom.com.

About BioSymetrics

For additional information, visit http://biosymetrics.com.

 

Media Contacts:                    

Korie Grill, Account Executive

Elevate Communications

kgrill@elevatecom.com

FDA developing new rules for artificial intelligence in medicine

By | Uncategorized | No Comments

It’s very encouraging to see the FDA showing forward thinking when it comes to AI/ML-based diagnostics. Even the best model can be outdated quickly given the changing data landscape, making frameworks like Augusta that allow for model refinement and evolution to be crucial. We welcome this mindset as we work with our partners to build more interpretable and more adaptable diagnostic models.

FDA developing new rules for artificial intelligence in medicine